Gynecologic care and concerns in the HIV-positive woman

Advanced Studies in Medicine

Volumn 5, Issue 8, 2005, Pages 403-410

  Anderson, Jean ^a,b,c  

^a Johns Hopkins HIV Women's Health Program   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Phipps 249 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; BORIC ACID; EFAVIRENZ; ESTRADIOL; ESTRADIOL CIPIONATE; ESTROGEN; ETHINYLESTRADIOL; FLUCONAZOLE; FOLLITROPIN; GESTAGEN; ITRACONAZOLE; LEVONORGESTREL; LOPINAVIR; MEDROXYPROGESTERONE ACETATE; MEGESTROL; NELFINAVIR; NEVIRAPINE; NONOXINOL 9; NORGESTREL; ORAL CONTRACEPTIVE AGENT; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SPERMICIDAL AGENT;

AMENORRHEA; ANOREXIA; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; CONDYLOMA; CONTRACEPTION; DYSPLASIA; FEMALE; FOLLITROPIN BLOOD LEVEL; GENERAL PRACTITIONER; GENITAL TRACT CANCER; GENITAL ULCER; GYNECOLOGIC DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MENSTRUAL IRREGULARITY; MENSTRUATION DISORDER; PATIENT; PELVIC INFLAMMATORY DISEASE; PRACTICE GUIDELINE; PREGNANCY; PREVALENCE; PRIMARY MEDICAL CARE; REVIEW; SPOTTING; SYSTEMATIC REVIEW; VAGINITIS; VIRUS INFECTION; VIRUS TRANSMISSION; WART VIRUS;

EID: 26044483548     PISSN: 15303004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Minkoff HL, Eisenberger-Matityahu D, Feldman J, Burk R, Clarke L. Prevalence and incidence of gynecologic disorders among women infected with human immunodeficiency virus. Am J Obstet Gynecol. 1999;180:824-830.
2. Frankel RE, Selwyn PA, Mezger J, Andrews S. High prevalence of gynecologic disease among hospitalized women with human immunodeficiency virus infection. Clin Infect Dis. 1997;25:706-712.
3. Harlow SD, Schuman P, Cohen M, et al. Effect of HIV infection on menstrual cycle length. J Acquir Immune Defic Syndr. 2000;24:68-75.
4. Ellerbrock TV, Wright TC, Bush TJ, Dole P, Brudney K, Chiasson MA. Characteristics of menstruation in women infected with human immunodeficiency virus. Obstet Gynecol. 1996;87:1030-1034.
5. Chirgwin KD, Feldman J, Muneyyirci-Delale O, Landesman S, Minkoff H. Menstrual function in human immunodeficiency virus-infected women without acquired immunodeficiency syndrome. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:489-494.
6. Clork RA, Mulligan K, Stamenovic E, et al. Frequency of anovulation and early menopause among women enrolled in selected adult AIDS clinical trials group studies. J Infect Dis. 2001;184:1325-1327.
7. Shah PN, Smith JR, Wells C, Barton SE, Kitchen VS, Steer PJ. Menstrual symptoms in women infected by the human immunodeficiency virus. Obstet Gynecol. 1994;83:397-400.
8. Harlow SD, Cohen M, Ohmit SE, et al. Substance use and psychotherapeutic medications: a likely contributor to menstrual disorders in women who are seropositive for human immunodeficiency virus. Am J Obstet Gynecol. 2003;188:881-886.
9. Stricker R. Hemostatic abnormalities in HIV diseases. Hematol Oncol Clin North Am. 1991;5:249-265.
10. Cejtin HE. Gynecologic issues in the HIV-infected woman. Obstet Gynecol Clin North Am. 2003;30:711-729.
11. Ball S. Amenorrhea in an HIV-infected woman. AIDS Read. 1998;8:92-94.
12. Augenbraun M, Feldman J, Chirgwin K, et al. Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women. Ann Intern Med. 1995;123:845-847
13. Wright PW, Hoesley CJ, Squires KE, Croom-Rivers A, Weiss HL, Gnann JW Jr. A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: correlation with CD4 cell count and plasma HIV-1 RNA level. Clin Infect Dis. 2003; 36:207-211.
14. Schacker T, Zeh J, Hu H, Shaughnessy M, Corey L. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis. 2002;186:1718-1725.
15. Centers for Disease Control and Prevention. 2002 sexually transmitted diseases treatment guidelines. MMWR Morb Mortal Wkly Rep. 2002;51:RR-6.
16. Anderson J, Clark RA, Watts DH, et al. Idiopathic genital ulcers in women infected with human immunodeficiency virus. J Acquir Immune Defic Syndr. 1996;3:343-347.
17. Taha TE, Hoover DR, Dallabetta GA, et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV AIDS. 1998;12:1699-1706.
18. Jamieson DJ, Duerr A, Klein RS, et al. Longitudinal analysis of bacterial vaginosis: findings from the HIV epidemiology research study. Obstet Gynecol. 2001;98:656-663.
19. Duerr A, Heilig CM, Meikle SF, et al. Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women: risk factors and severity. Obstet Gynecol. 2003;101:548-556.
20. Warren D, Klein RS, Sobel J, et al. A multicenter study of bacterial vaginosis in women with or at risk for human immunodeficiency virus infection. Infect Dis Obstet Gynecol. 2001;9:133-141.
21. Martin HL Jr, Nyange PM, Richardson BA, et al. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis. 1998;178:1053-1059.
22. Chesson HW, Blandford JM, Pinkerton SD. Estimates of the annual number and cost of new HIV infections among women attributable to trichomoniasis in the United States. Sex Transm Dis. 2004;31:547-551.
23. Taha TE, Gray RH, Kumwenda NI, et al. HIV infection and disturbances of vaginal flora during pregnancy. J Acquit Immune Defic Syndr Hum Retrovirol. 1999;20:52-59.
24. Schuman P, Sobel JD, Ohmit SE, et al. Mucosal candidal colonizotion and candidiasis in women with or at risk for human immunodeficiency virus infection. HIV Epidemiology Research Study (HERS) Group. Clin Infect Dis. 1998;27:1161-1167.
25. Spinillo A, Michelone G, Cavanna C, Colonna L, Capuzzo E, Nicola S. Clinical and microbiological characteristics of symptomatic vulvovaginal candidiasis in HIV-seropositive women. Genitourin Med. 1994;70:268-272.
26. Duerr A, Sierra MF, Feldman J, Clarke LM, Ehrlich I, DeHovitz J. Immune compromise and prevalence of Candida vulvovaginitis in human immunodeficiency virus-infected women. Obstet Gynecol. 1997;90:252-256.
27. Sobel JD, Ohmit SE, Schuman P, et al. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis. 2001;183:286-293.
28. Abularach S, Anderson J. Gynecologic problems. In: Anderson J, ed. A Guide to the Clinical Care of Women With HIV. Washington, DC: Department of Health and Human Services, HIV/AIDS Bureau; In press.
29. Schuman P, Capps L, Peng G, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997;126:689-696.
30. US Public Health Service (USPHS), Infectious Diseases Society of America (IDSA), Panel on clinical practices for treatment of HIV infection. Guidelines for the Prevention of Opportunistic Infections in Persons Infected With Human Immunodeficiency Virus. Available at: http://www.oidsinfo.nih.gov. Accessed March 22, 2005.
31. Ness RB, Hillier SL, Richter HE, et al. Douching in relation to bacterial vaginosis, lactobacilli, and facultative bacteria in the vagina. Obstet Gynecol. 2002;100:765.
32. Kerr-Layton JA, Stamm CA, Peterson LS, McGregor JA. Chronic plasma cell endometritis in hysterectomy specimens of HIV-infected women: a retrospective analysis. Infect Dis Obstet Gynecol. 1998;6:186-190.
33. Barbosa C, Macasaet M, Brockmann S, Sierra MF, Xia Z, Duerr A. Pelvic inflammatory disease and human immunodeficiency virus infection. Obstet Gynecol. 1997;89:65-70.
34. Cohen CR, Sinei S, Reilly M, et al. Effect of human immunodeficiency virus type 1 infection upon acute salpingitis: a laparoscopic study. J Infect Dis. 1998;178:1352-1358.
35. Kamenga MC, De Cock KM, St Louis ME, et al. The impact of human immunodeficiency virus infection on pelvic inflammatory disease: a case-control study in Abidjan, Ivory Coast. Am J Obstet Gynecol. 1995;172:919-925.
36. Irwin KL, Moorman AC, O'Sullivan MJ, et al. Influence of human immunodeficiency virus infection on pelvic inflammatory disease. Obstet Gynecol. 2000;95:525-534.
37. Ahdieh L, Klein RS, Burk R, et al. Prevalence, incidence and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis. 2001;184:682-690.
38. Silverberg MJ, Ahdieh L, Munoz A, et al. The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis. 2002;29:427-435.
39. Jamieson DJ, Duerr A, Burk R, et al. Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. Am J Obstet Gynecol. 2002;186:21-27.
40. Luque AE, Demeter LM, Reichman RC. Association of human papillomavirus infection and disease with magnitude of human immunodeficiency virus type 1 (HIV-1) RNA plasma level among women with HIV-1 infection. J Infect Dis. 1999;179:1405-1409.
41. Minkaff H, Feldman J, DeHovitz J, Landesman S, Burk R. A longitudinal study of human papillomavirus carriage in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women. Am J Obstet Gynecol. 1998;178:982-986.
42. Maiman M. Management of cervical neoplasia in human immunodeficiency virus-infected women. J Natl Cancer Inst Monogr. 1998:43-49.
43. Six C, Heard I, Bergeron C, et al. Comparative prevalence, incidence and short-term prognosis of cervical squamous intraepithelial lesions amongst HIV-positive and HIV-negative women. AIDS. 1998;12:1047-1056.
44. Sewell C, Keller J, Anderson J. Immunologic, virologic, and histologic correlates of ASCUS/LSIL and progression in HIV-positive women. Abstract MoPeB2228. Paper presented at: XIII International AIDS Conference; July 9-14, 2000; Durban, South Africa.
45. Maiman M, Fruchter RG, Serur E, Remy JC, Feuer G, Boyce J. Human immunodeficiency virus infection and cervical neoplasia. Gynecol Oncol. 1990;38:377-382.
46. Petry KU, Kochel H, Bade U, et al. Human papillomavirus is associated with the frequent detection of warty and bosaloid high-grade neoplasia of the vulva and cervical neoplasia among immunocompromised women. Gynecol Oncol. 1996;60:30-34.
47. Hillemanns P, Ellerbrock W, McPhillips S, et al. Prevalence of anal human papillomavirus infection and anal cytologic abnormalities in HIV-seropositive women. AIDS. 1996; 10:1641-1647.
48. American College of Obstetricians and Gynecologists. Cervical cytology: evaluation and management of abnormalities. Technical Bulletin Number 183. August 1993.
49. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002; 287:2120-2129.
50. Palefsky JM, Holly EA, Ralston ML, Da Costa M, Greenblatt RM. Prevalence and risk factors far anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis. 2001;183:383-391.
51. Palefsky JM, Holly EA, Hogeboom CJ, Berry JM, Jay N, Darragh TM. Anal cytology as a screening toal for anal squamous intraepithelial lesions. J Acquit Immune Defic Syndr Hum Retroviral. 1997;14:415-422.
52. Fruchter RG, Maiman M, Sedlis A, Bortley L, Camilien L, Arrastia CD. Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet Gynecol. 1996;87:338-344.
53. Holcomb K, Matthews RP, Chapman JE, et al. The efficacy of cervical conization in the treatment of cervical intraepithelial neoplasia in HIV-positive women. Gynecol Oncol. 1999;74:428-431.
54. Keller J. Abstract 2096: XIV International AIDS Conference. Paper presented at: XIV International AIDS Conference; July 2002; Barcelona, Spain.
55. Boardman LA, Peipert JF, Hogan JW, Cooper AS. Positive cone biopsy specimen margins in women infected with the human immunodeficiency virus. Am J Obstet Gynecol. 1999;181:1395-1399.
56. CDC. 1993 revised classification for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41:1-19.
57. Lomalisa P, Smith T, Guidazzi F. Human immunodeficiency virus infection and invasive cervical cancer in South Africa. Gynecol Oncol. 2000;77:460-463.
58. Klevens RM, Fleming PL, Mays MA, Frey R. Characteristics of women with AIDS and invasive cervical cancer. Obstet Gynecol. 1996;88:269-273.
59. Mbulaiteye SM, Biggar RJ, Gaedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS J Acquir Immune Defic Syndr. 2003;32:527-533.
60. Massad LS, Seaberg EC, Watts DH, et al. Low incidence of invasive cervical cancer among HIV-infected US women in a prevention program. AIDS. 2004;18:109-113.
61. Heard I, Tassie JM, Kazatchkine MD, Orth G. Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS. 2002;16:1799-1802.
62. Minkoff H, Ahdieh L, Massad LS, et al. The effect of highly active antiretroviral therapy an cervical cytolagic changes associated with ancogenic HPV among HIV-infected women. AIDS. 2001;15:2157-2164.
63. Palefsky JM, Hally EA, Ralston ML, et al. Effect of highly active antiretroviral therapy on the natural history of anal squamaus intraepithelial lesions and anal human papillomavirus infection. J Acquir Immune Defic Syndr. 2001;28:422-428.
64. Lillo FB, Ferrari D, Veglia F, et al. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis. 2001;184:547-551.
65. Mostad SB, Overbaugh J, DeVange DM, et al. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet. 1997;350:922-927.
66. Wang CC, McClelland RS, Overbaugh J, et al. The effect of hormonal contraception on genital tract shedding of HIV-1. AIDS. 2004;18:205-209.
67. Kiddugavu M, Makumbi F, Wawer MJ, et al. Hormonal contraceptive use and HIV-1 infection in a population-based cohort in Rakai, Uganda. AIDS. 2003;17:233-240.
68. Panel on Clinical Practices for the Treatment of HIV Infection. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Available at: http://aidsinfo.nih.gov/guidelines/adult/AA_040705.pdf. Accessed May 19, 2005.
69. Lazzarin A, Saracca A, Musicca M, Nicolosi A. Man-to-woman sexual transmission of the human immunodeficiency virus. Risk factors related to sexual behavior, man's infectiousness, and woman's susceptibility. Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med. 1991; 151:2411-2416.
70. Morrison CS, Sekadde-Kigondu C, Sinei SK, Weiner DH, Kwok C, Kokonya D. Is the intrauterine device appropriate contraception for HIV-1-infected women? BJOG. 2001; 108:784-790.
71. Richardson B. Use of sexually transmitted disease risk assessment algorithms for selection of intrauterine device candidates. Contraception. 1999;59:97-106.
72. Richardson BA. Nonoxynol-9 as a vaginal microbicide for prevention of sexually transmitted infections: it's time to move on. JAMA. 2002;287:1171-1172.